The migrastatin family: Discovery of potent cell migration inhibitors by chemical synthesis

Journal of the American Chemical Society

Volumn 126, Issue 36, 2004, Pages 11326-11337

  Gaul, Christoph ^a   Njardarson, Jón T ^a   Shan, Dandan ^b   Dorn, David C ^a   Wu, Kai Da ^a   Tong, William P ^a   Huang, Xin Yun ^b   Moore, Malcolm A S ^a   Danishefsky, Samuel J ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOLS; ASSAYS; CONDENSATION; SYNTHESIS (CHEMICAL); TUMORS;

ANTIMETASTATIC PROPERTIES; CELL MIGRATION; NATURAL PRODUCTS;

CELLS;

ANTIMETASTATIC AGENT; LEWIS ACID; MACROCYCLIC COMPOUND; MACROLIDE; MIGRASTATIN; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CELL DEATH; CELL MIGRATION; DRUG POTENCY; LEUKOCYTE MIGRATION INHIBITION TEST; RING CLOSING METATHESIS; SOLID TUMOR; STEREOCHEMISTRY; SYNTHESIS; TISSUE REGENERATION; WOUND HEALING;

ALCOHOLS; ANIMALS; CELL MOVEMENT; ENDOTHELIUM, VASCULAR; HUMANS; KETONES; LACTONES; MACROLIDES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PIPERIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4544233786     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja048779q     Document Type: Article

References (110)

1. Fenteany, G.; Zhu, S. Curr. Top. Med. Chem. 2003, 3, 593-616.
2. Lauffenburger, D. A.; Horwitz, A. F. Cell 1996, 84, 359-369.
3. Carmeliet, P. Nat. Med. 2003, 9, 653-660.
4. For research efforts toward anti-angiogenic agents, consult: (a) Brower, V. Nat. Biotechnol. 1999, 17, 963-968.
5. (b) Klohs, W. D.; Hamby, J. M. Curr. Opin. Biotechnol. 1999, 10, 544-549.
6. (c) Deplanque, G.; Harris, A. L. Eur. J. Cancer 2000, 36, 1713-1724.
7. (d) Scappaticci, F. A. J. Clin. Oncol. 2002, 20, 3906-3927.
8. (e) Cristofanilli, M.; Charnsangavej, C.; Hortobagyi, G. N. Nat. Rev. Drug Discovery 2002, 1, 415-426.
9. (f) Kerbel, R.; Folkman, J. Nat. Rev. Cancer 2003, 2, 727-739.
10. For early syntheses of natural product angiogenesis inhibitors, see: (g) Corey, E. J.; Snider, B. B. J. Am. Chem. Soc. 1972, 94, 2549-2550.
11. (h) Corey, E. J.; Dittami, J. P. J. Am. Chem. Soc. 1985, 107, 256-257.
12. (i) Corey, E. J.; Guzman-Perez, A.; Noe, M. C. J. Am. Chem. Soc. 1994, 116, 12109-12110.
13. Woodhouse, E. C.; Chuaqui, R. F.; Liotta, L. A. Cancer 1997, 80 (S8), 1529-1537.
14. For comprehensive reviews, see: (a) Harris, C. R.; Danishefsky, S. J. J. Org. Chem. 1999, 64, 8434-8456.
15. (b) Stachel, S. J.; Biswas, K.; Danishefsky, S. J. Curr. Pharm. Des. 2001, 7, 1277-1290.
16. Danishefsky, S. J.; Masters, J. J.; Young, W. B.; Link, J. T.; Snyder, L. B.; Magee, T. V.; Jung, D. K.; Isaacs, R. C. A.; Bornmann, W. G.; Alaimo, C. A.; Coburn, C. A.; DiGrandi, M. J. J. Am. Chem. Soc. 1996, 118, 2843-2859.
17. For the synthesis and biological evaluation of radicicol and cyclopropyl-radicicol, see: (a) Garbaccio, R. M.; Stachel, S. J.; Baeschlin, D. K.; Danishefsky, S. J. J. Am. Chem. Soc. 2001, 123, 10903-10908.
18. (b) Yamamoto, K.; Garbaccio, R. M.; Stachel, S. J.; Solit, D. B.; Chiosis, G.; Rosen, N.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2003, 42, 1280-1284.
19. (c) Yang, Z. Q.; Danishefsky, S. J. J. Am. Chem. Soc. 2003, 125, 9602-9603.
20. For the synthesis and evaluation of TMC-95A/B, see: (a) Lin, S.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2001, 40, 512-515.
21. (b) Yang, Z. Q.; Kwok, B. H.; Lin, S.; Koldobskiy, M. A.; Crews, C. M.; Danishefsky, S. J. Chembiochem 2003, 6, 508-513.
22. For more information about clinical trials of dEpoB, visit: www.kosan.com.
23. For the synthesis and biological evaluation of recent epothilone analogues, see: (a) Rivkin, A.; Yoshimura, F.; Gabarda, A. E.; Chou, T. C.; Dong, H.; Tong, W. P.; Danishefsky, S. J. J. Am. Chem. Soc. 2003, 125, 2899-2901.
24. (b) Yoshimura, F.; Rivkin, A.; Gabarda, A. E.; Chou, T. C.; Dong, H.; Sukenick, G.; Morel, F. F.; Taylor, R. E.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2003, 42, 2518-2521.
25. For the isolation of epoxyquinol A and B, see: (a) Kakeya, H.; Onose, R.; Koshino, H.; Yoshida, A.; Kobayashi. K.; Kageyama, S. I.; Osada, H. J. Am. Chem. Soc. 2002, 124, 3496-3497.
26. (b) Kakeya, H.; Onose, R.; Yoshida, A.; Koshino, H.; Osada, H. J. Antibiot. 2002, 55, 829-831.
27. For the synthesis of epoxyquinol A and B, see: (c) Shoji, M.; Yamaguchi, J.; Kakeya, H.; Osada, H.; Hayashi, Y. Angew. Chem., Int. Ed. 2002, 41, 3192-3194.
28. (d) Chaomin, L.; Bardhan, S.; Pace, E. A.; Liang, M. C.; Gilmore, T. D.; Porco, J. A., Jr. Org. Lett. 2002, 4, 3267-3270.
29. (e) Mehta, G.; Islam, K. Tetrahedron Lett. 2003, 44, 3569-3572.
30. For the isolation of trachyspic acid, see: (a) Shiozawa, H.; Takahashi, M.; Takatsu, T.; Kinoshita, T.; Tanzawa, K.; Hosoya, T.; Furuya, K.; Furihata, K.; Seto, H. J. Antibiot. 1995, 48, 357-362.
31. For the synthesis of trachyspic acid, see: (b) Hirai, K.; Ooi, H.; Esumi, T.; Iwabuchi, Y.; Hatakeyama, S. Org. Lett. 2003, 5, 857-859.
32. For the isolation of azaspirene, see: (a) Asami, Y.; Kakeya, H.; Onose, R.; Yoshida, A.; Matsuzaki, H.; Osada, H. Org. Lett. 2002, 4, 2845-2848.
33. For the synthesis of azaspirene, see: (b) Hayashi, Y.; Shoji, M.; Yamaguchi, J.; Sato, K.; Yamaguchi, S.; Mukaiyama, T.; Sakai, K.; Asami, Y.; Kakeya, H.; Osada, H. J. Am. Chem. Soc. 2002, 124, 12078-12079.
34. A screening approach revealed evodiamine as a potent anti-invasive and anti-metastatic agent: (a) Ogasawara, M.; Matsubara, T.; Suzuki, H. Biol. Pharm. Bull. 2001, 24, 720-723.
35. (b) Ogasawara, M.; Matsubara, T.; Suzuki, H. Biol. Pharm. Bull. 2001, 24, 917-920.
36. (c) Ogasawara, M.; Matsunaga, T.; Takahashi, S.; Saiki, I.; Suzuki, H. Biol. Pharm. Bull. 2002, 25, 1491-1493.
37. For the isolation, synthesis, and discussion of the anti-angiogenic properties of the motuporamines, see: (a) Williams, D. E.; Lassota, P.; Andersen, R. J. J. Org. Chem. 1998, 63, 4838-4841.
38. (b) Roskelley, C. D.; Williams, D. E.; McHardy, L. M.; Leong, K. G.; Troussard, A.; Karsan, A.; Andersen, R. J.; Dedhar, S.; Roberge, M. Cancer Res. 2001, 61, 6788-6794.
39. (c) Williams, D. E.; Craig, K. S.; Patrick, B.; McHardy, L. M.; van Soest, R.; Roberge, M.; Andersen, R. J. J. Org. Chem. 2002, 67, 245-258.
40. For the discovery of the anti-angiogenic properties of borrelidin, see: (a) Wakabayashi, T.; Kageyama, R.; Naruse, N.; Tsukahara, N.; Funahashi, Y.; Kitoh, K.; Watanabe, Y. J. Antibiot. 1997, 50, 671-676.
41. For the synthesis of borrelidin, see: (b) Duffey, M. O.; LeTiran, A.; Morken, J. P. J. Am. Chem. Soc. 2003, 125, 1458-1459.
42. For the discovery of the anti-angiogenic properties of terpestacin, see: (a) Jung, H. J.; Lee, H. B.; Kim, C. J.; Rho, J. R.; Shin, J.; Kwon, H. J. J. Antibiot. 2003, 56, 492-496.
43. For the synthesis of terpestacin, see: (b) Tatsuta, K.; Masuda, N. J. Antibiot. 1998, 51, 602-606.
44. (c) Myers, A. G.; Siu, M.; Ren, F. J. Am. Chem. Soc. 2002, 124, 4230-4232.
45. (d) Chan, J.; Jamison, T. F. J. Am. Chem. Soc. 2003, 125, 11514-11515.
46. (a) Nakae, K.; Yoshimoto, Y.; Sawa, T.; Homma, Y.; Hamada, M.; Takeuchi, T.; Imoto, M. J. Antibiot. 2000, 53, 1130-1136.
47. (b) Nakae, K.; Yoshimoto, Y.; Ueda, M.; Sawa, T.; Takahashi, Y.; Naganawa, H.; Takeuchi, T.; Imoto, M. J. Antibiot. 2000, 53, 1228-1230.
48. (c) Takemoto, Y.; Nakae, K.; Kawatani, M.; Takahashi, Y.; Naganawa, H.; Imoto, M. J. Antibiot. 2001, 54, 1104-1107.
49. (d) Nakamura, H.; Takahashi, Y.; Naganawa, H.; Nakae, K.; Imoto, M.; Shiro, M.; Matsumura, K.; Watanabe, H.; Kitahara, T. J. Antibiot. 2002, 55, 442-444.
50. Woo, E. J.; Starks, C. M.; Carney, J. R.; Arslanian, R.; Cadapan, L.; Zavala, S.; Licari, P. J. Antibiot. 2002, 55, 141-146.
51. Cycloheximide (CHX) is a glutarimide antibiotic that inhibits protein synthesis. CHX is widely used for studies of cell death and is commercially available as Ready Made solution by Sigma. For a more recent leading article, see: Mattson, M. P.; Furukawa, K. Apoptosis 1997, 2, 257-264.
52. For a recent synthesis of streptimidone, a glutarimide antibiotic, see: Kondo, H.; Oritani, T.; Kiyota, H. Eur. J. Org. Chem. 2000, 3459-3462.
53. For the original discovery of the anti-angiogenic properties of thalidomide, see: (a) D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4082-4085.
54. For recent discussions of the use of thalidomide in anti-cancer therapy, see: (b) Thomas, D. A.; Kantarjian, H. M. Curr. Opin. Oncol. 2000, 12, 564-573.
55. (c) Raje, N.; Anderson, K. C. Curr. Opin. Oncol. 2002, 14, 635-646.
56. (d) Dredge, K.; Dalgleish, A. G.; Marriott, J. B. Anti-Cancer Drugs 2003, 14, 331-335.
57. (e) Capitosti, S. M.; Hansen, T. P.; Brown, M. L. Bioorg. Med. Chem. 2004, 12, 327-336.
58. Sugawara, K.; Nishiyama, Y.; Toda, S.; Komiyama, N.; Hatori, M.; Moriyama, T.; Sawada, Y.; Kamei, H.; Konishi, M.; Oki, T. J. Antibiot. 1992, 45, 1433-1441.
59. (a) Karwowski, J. P.; Jackson, M.; Sunga, G.; Sheldon, P.; Poddig, J. B.; Kohl, W. L.; Adam, S. J. Antibiot. 1994, 47, 862-869.
60. (b) Hochlowski, J. E.; Whittern, D. N.; Hill, P.; McAlpine, J. B. J. Antibiot. 1994, 47, 870-874.
61. (c) Kadam, S.; McAlpine, J. B. J. Antibiot. 1994, 47, 875-880.
62. (a) Takayasu, Y.; Tsuchiya, K.; Aoyama, T.; Sukenaga, Y. J. Antibiot. 2001, 54, 1111-1115.
63. (b) Takayasu, Y.; Tsuchiya, K.; Sukenaga, Y. J. Antibiot. 2002, 55, 337-340.
64. Gaul, C.; Njardarson, J. T.; Danishefsky, S. J. J. Am. Chem. Soc. 2003, 125, 6042-6043.
65. Njardarson, J. T.; Gaul, C.; Shan, D.; Huang, X. Y.; Danishefsky, S. J. J. Am. Chem. Soc. 2004, 126, 1038-1040.
66. Danishefsky, S. J.; Kitahara, T. J. Am. Chem. Soc. 1974, 96, 7807-7808.
67. (a) Danishefsky, S. J. Aldrichimica Acta 1986, 19, 59-69.
68. (b) Danishefsky, S. J. Chemtracts 1989, 2, 273-297.
69. Gaul, C.; Danishefsky, S. J. Tetrahedron Lett. 2002, 43, 9039-9042.
70. S)-3-benzyloxy-1,2-propanediol 7 is commercially available (Fluka, Aldrich), but only at a high cost. Compound 7 can be easily prepared from inexpensive starting materials. (a) Xiang, G.; McLaughlin, L. W. Tetrahedron 1998, 54, 375-392.
71. (b) Kitaori, K.; Furukawa, Y.; Yoshimoto, H.; Otera, J. Tetrahedron 1999, 55, 14381-14390.
72. Reetz, M. T.; Kessler, K. J. Org. Chem. 1985, 50, 5434-5436.
73. Danishefsky, S. J.; Yan, C. F.; Singh, R. K.; Gammill, R. B.; McCurry, P. M., Jr.; Fritsch, N.; Clardy, J. J. Am. Chem. Soc. 1979, 101, 7001-7008.
74. For chelation-controlled cyclocondensations of α-alkoxy aldehydes with synergistically activated dienes, see: Danishefsky, S. J.; Pearson, W. H.; Harvey, D. F.; Maring, C. J.; Springer, J. P. J. Am. Chem. Soc. 1985, 107, 1256-1268.
75. Luche, J. L.; Gemal, A. L. J. Am. Chem. Soc. 1979, 101, 5848-5849.
76. Ferrier, R. J. J. Chem. Soc. 1964, 5443-5450.
77. (a) Katzenellenbogen, J. A.; Crumrine, A. L. J. Am. Chem. Soc. 1976, 95, 4925-4935.
78. (b) Ahmar, M.; Duyck, C.; Fleming, I. J. Chem. Soc., Perkin Trans. 1 1998, 2721-2732.
79. Tebbe, F. N.; Parshall, G. W.; Reddy, G. S. J. Am. Chem. Soc. 1978, 100, 3611-3613.
80. For initial reports of Grubbs-II catalyst 16, see: (a) Scholl, M.; Trnka, T. M.; Morgan, J. P.; Grubbs, R. H. Tetrahedron Lett. 1999, 40, 2247-2250.
81. (b) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953-956.
82. For the first report of these new, optimized RCM conditions, see: (a) Yamamoto, K.; Biswas, K.; Gaul, C.; Danishefsky, S. J. Tetrahedron Lett. 2003, 44, 3297-3299.
83. The same reaction conditions were also applied to the first total synthesis of epothilone 490: (b) Biswas, K.; Lin, H.; Njardarson, J. T.; Chappell, M. D.; Chou, T. C.; Guan, Y.; Tong, W. P.; He, L.; Horwitz, S. B.; Danishefsky, S. J. J. Am. Chem. Soc. 2002, 124, 9825-9832.
84. Jorgensen, M.; Iversen, E. H.; Paulsen, A. L.; Madsen, R. J. Org. Chem. 2001, 66, 4630-4634.
85. Lee, W. W.; Chang, S. Tetrahedron: Asymmetry 1999, 10, 4473-4475.
86. (a) Danishefsky, S. J.; Kato, N.; Askin, D.; Kerwin, J. F., Jr. J. Am. Chem. Soc. 1982, 104, 360-362.
87. (b) Eng, H. M.; Myles, D. C. Tetrahedron Lett. 1999, 40, 2279-2282.
88. Crystallographic data (excluding structural data) for compound 24 have been deposited with the Cambridge Crystallographic Data Centre (CCDC) as Deposition No. CCDC 230121.
89. Dess, D. B.; Martin, J. C. J. Am. Chem. Soc. 1991, 113, 7277-7287.
90. Abiko, A.; Liu, J. F.; Masamune, S. J. Am. Chem. Soc. 1997, 119, 2586-2587.
91. Evans, D. A.; Tedrow, J. S.; Shaw, J. T.; Downey, C. W. J. Am. Chem. Soc. 2002, 124, 392-393.
92. For examples of the direct addition of lithiated dimethyl methylphosphonate to esters, see, for example: (a) Edmonds, M. K.; Abell, A. D. J. Org. Chem. 2001, 66, 3747-3752.
93. (b) Smith, A. B., III; Frohn, M. Org. Lett. 2001, 3, 3979-3982.
94. Egawa, Y.; Suzuki, M.; Okuda, T. Chem. Pharm. Bull. 1963, 11, 589-595.
95. Blanchette, M. A.; Choy, W.; Davis, J. T.; Essenfeld, A. M.; Masamune, S.; Roush, W. R.; Sakai, T. Tetrahedron Lett. 1984, 25, 2183-2186.
96. Mahoney, W. S.; Brestensky, D. M.; Stryker, J. M. J. Am. Chem. Soc. 1988, 110, 291-293. The Stryker reagent provided by Aldrich performed poorly in the conjugate reduction. The reagent provided by Fluka or prepared by us led to superior results.
97. (a) Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. Bull. Chem. Soc. Jpn. 1979, 52, 1989-1993.
98. For a recent example, see: (b) Song, F.; Fidanze, S.; Benowitz, A. B.; Kishi, Y. Org. Lett. 2002, 4, 647-650.
99. (a) Mukaiyama, T.; Usui, M.; Shimada, E.; Saigo, K. Chem. Lett. 1975, 1045-1048.
100. (b) Mukaiyama, T. Angew. Chem., Int. Ed. Engl. 1979, 18, 707-721.
101. Boden, E. P.; Keck, G. E. J. Org. Chem. 1985, 50, 2394-2395.
102. Stachel, S. J.; Lee, C. B.; Spassova, M.; Chappell, M. D.; Bornmann, W. G.; Danishefsky, S. J. J. Org. Chem. 2001, 66, 4369-4378 (includes an example for the Mitsunobu-Staudinger sequence).
103. Chun, J.; Li, G.; Byun, H. S.; Bittman, R. J. Org. Chem. 2002, 67, 2600-2605.
104. For a recent example, see: Dixon, D. J.; Krause, L.; Ley, S. V. J. Chem. Soc., Perkin Trans. 1 2001, 2516-2518.
105. (a) Trost, B. M.; Bunt, R. C.; Pulley, S. R. J. Org. Chem. 1994, 59, 4202-4205.
106. (b) Seco, J. M.; Latypov, S. K.; Quinoa, E.; Riguera, R. Tetrahedron 1997, 53, 8541-8564.
107. (c) Seco, J. M.; Quinoa, E.; Riguera, R. Tetrahedron: Asymmetry 2000, 11, 2781-2791.
108. Li, D. R.; Xia, W. J.; Shi, L.; Tu, Y. Q. Synthesis 2003, 41-44.
109. Prakash, G. K. S.; Krishnamurti, R.; Olah, G. A. J. Am. Chem. Soc. 1989, 111, 393-395.
110. MCF-7, another human breast cancer cell line, did not respond at all.